Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 0.71 |
| ▸ | PIK3R1 | P27986 | 17/20 | 0.71 |
| ▸ | PIK3CG | P48736 | 13/20 | 0.71 |
| ▸ | PIK3CB | P42338 | 11/20 | 0.71 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2509587 | 1.00 | PIK3CD (0.71) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL2507372 | 1.00 | PIK3CD (0.71) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL2505545 | 0.85 | PIK3CD (0.71) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL2505791 | 0.85 | PIK3CD (0.71) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL2505749 | 0.85 | PIK3CD (0.71) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL2512016 | 0.85 | PIK3CD (0.71) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL2505255 | 0.85 | PIK3CD (0.71) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL2507668 | 0.85 | PIK3CD (0.71) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL2511250 | 0.84 | PIK3CD (0.70) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA | |
| SCHEMBL2505912 | 0.84 | PIK3CD (0.70) | PIK3CDPIK3R1PIK3CGPIK3CBPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575183-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2013-11-05 | — | — | US | claimed |
| US-20110245257-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-10-06 | — | — | US | claimed |
| US-8575183-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2013-11-05 | — | — | US | disclosed |
| WO-2012146667-A1 | IMIDAZOPYRIDINE DERIVATIVES AS PI3K INHIBITORS | ALMIRALL, S.A. (ES) | 2012-11-01 | — | — | WO | disclosed |
| US-20110245257-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245257-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, BCL9, MALT1 | PIK3CD 16/4885PIK3R1 48/4885PIK3CG 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.